This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Epoxide hydrolase 2 (EPHX2; CEH)	Cell culture and mouse studies suggest a combination of fish oil-derived epoxy docosapentaenoic acids (EDPs) and EPHX2 inhibitors could be useful for treating cancer. In a mouse model for breast cancer, EDP plus an EPHX2 inhibitor caused more potent inhibition of tumor vascularization and growth than either treatment alone. Next steps could include further preclinical evaluation of EPHX2 inhibitors in cancer models. Arete Therapeutics Inc., a company cofounded by the study's corresponding author, had EPHX2 inhibitors in Phase II testing for type 2 diabetes before ceasing operations.	Soluble epoxide hydrolase inhibitors patented; available for licensing from the University of California, Davis Contact: Barbara Boczar, University of California, Davis, Calif. e-mail: baboczar@ucdavis.edu	Zhang, G. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online April 3, 2013; doi:10.1073/pnas.1304321110 Contact: Bruce D. Hammock, University of California, Davis, Calif. e-mail: bdhammock@ucdavis.edu
SciBX 6(16); doi:10.1038/scibx.2013.383 Published online April 25, 2013				